Wikipedia
Neratinib
Neratinib (HKI-272) is a tyrosine kinase inhibitor under investigation for the treatment of breast cancer and other solid tumours.
It is in development for the treatment of early- and late-stage HER2-positive breast cancer.
Like lapatinib and afatinib, it is a dual inhibitor of the human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases.